Genetic Engineering & Biotechnology News

JUL 2017

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 11 of 45

10 | JULY 2017 | | Genetic Engineering & Biotechnology News Drug Discovery Feature Roundup Once confined to disease modeling and drug-safety testing, 3D cell culture is expanding in multiple directions, exploring new possibilities in basic research, drug discovery, and therapeutics. In basic research, 3D cell culture is being used to establish models of disease and unravel the mysteries of differentiation. In drug discovery, 3D cell culture is demonstrating that it isn't just for toxicology—it can be adapted for target identification and drug candidate screening, too. And in therapeutics, 3D cell culture promises to realize several exciting applications, from patient- specific drug-efficacy screening to the manufacturing of bioprinted organs. These possibilities are coming within our grasp because 3D cell culture, unlike 2D cell culture, has depth—and not just in the obvious geometrical sense. 3D cell culture captures structural and organizational variations, and hence physiological variations, that can help it represent real, living tissue far better than 2D cell culture ever could. 3D cell culture, besides being more convenient than animal models (and relatively free of ethical issues), permits extraordinary control—from the genetic level and beyond. In addition to raising the possibility of patient-specific models, 3D cell culture could progress beyond relatively simple self-aggregated spheroids to replicate all manner of developmental contingencies in environments consisting of multiple cell types and diverse extracellular elements. And if that means manipulating cells magnetically or embedding them in microfluidic structures, so be it. Realizing these heady possibilities is a daunting challenge. Fortunately, it isn't beyond GEN's panel of experts. Consider them the grandmasters of 3D cell culture. For your edification, they have answered GEN's questions about 3D cell culture's opening game, as well as how the endgame may develop. (For the middlegame—3D culture's current challenges—please read the unabridged, online version of this roundup). Watch This 3D Cell Culture Space E X P E R T P A N E L Joy Aho, Ph.D. Manager, Stem Cell Research, Bio-Techne Peter Banks, Ph.D. Scientific Director, BioTek Instruments Richard Eglen, Ph.D. Vice President and General Manager, Corning Life Sciences Del Trezise, Ph.D. Director, R&D, Essen BioScience, now part of Sartorius Stedim Biotech Kristina Klette, Ph.D. Scientific Lead Group Manager and Scientific Leader, Cellular and Protein Sciences, Hamilton Robotics Patrick Guye, Ph.D. Chief Scientific Officer, InSphero 10 | JULY 2017 | | Genetic Engineering & Biotechnology News See more Panelists on page 11 Patrick Kugelmeier, Dr. med. Director of Science, Kugelmeiers

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - JUL 2017